Active Ingredient(s):Lurbinectedin FDA Approved: * June 15, 2020 Pharm Company: *JAZZ Category:Cancer
Lurbinectedin, sold under the brand name Zepzelca, is a medication for the treatment of adults with metastatic small cell lung cancer (SCLC) with disease progression on or after platinum-based chemotherapy.
The most common side effects include leukopenia, lymphopenia, fatigue, anemia, neutropenia, increased creatinine, increased alanine aminotransferase, increased glucose, thrombocytopenia, nausea, decreased appetite, musculoskeletal pa...
* May have multiple approval dates, manufacturers, or labelers.
Zepzelca .5 mg/ml Intravenous Injection, Powder, Lyophilized, for Solution